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SYNOPSIS 
Human T-lymphotropic virus type 1 (HTLV-1) is associated with a number of human 
diseases. Its protease is essential for the virus replication, and similar to the human 
immunodeficiency virus type 1 (HIV-1) protease, it is a potential target for 
chemotherapy. The primary sequence of HTLV-1 protease is substantially longer 
compared to that of HIV-1 protease, and the role of the ten C-terminal residues is 
controversial. We have expressed C-terminally truncated forms of the HTLV-1 
protease with and without N-terminal histidine tags. Removal of five C-terminal 
residues caused four- to fourtyfold decrease of the specificity constants, while the 
removal of an additional five C-terminal residues rendered the protease completely 
inactive. The addition of the N-terminal histidine tag dramatically decreased the 
activity of the HTLV-1 protease forms. Pull-down experiments carried out with 
histidine-tagged forms, gelfiltration experiments and dimerization assays provided the 
first unequivocal experimental data for the role of the C-terminal residues in 
dimerization of the enzyme. There is a hydrophobic tunnel on the surface of HTLV-1 
protease close to the terminal ends that is absent in HIV-1 protease. This hydrophobic 
tunnel can accommodate the C-terminal extra residues of HTLV-1 protease, which 
was predicted to stabilize the dimer of the full-length enzyme and provides an 
alternative target site for protease inhibition. 
 
Key words: retroviral protease, HTLV-1, dimerization, C-terminal residues, gel 
filtration, pull down assay, molecular modeling  
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INTRODUCTION 
Human T-lymphotropic virus type 1 (HTLV-1), a retrovirus similar to human 
immunodeficiency virus type 1 (HIV-1), has been etiologically associated with a 
number of diseases including adult T-cell leukemia/lymphoma (ATL) and tropical 
spastic paraparesis/HTLV-1 associated myelopathy (TSP/HAM) (reviewed in Ref. 
[1]). Approximately 10-20 million people are infected worldwide, and about 5 % of 
them develop one form of the diseases [2]. Currently there is no vaccine and no 
satisfactory therapy available to prevent infection or treat the patients [2]. Although 
active virus replication may not be required for the progression of all HTLV-1 related 
diseases, blocking viral replication with AZT or lamivudine can have a therapeutic 
effect [3]. Based on the successful clinical inhibitors of the protease (PR) of HIV-1, 
the PR of HTLV-1 is also a potential target for chemotherapy [4,5]. HTLV-1 PR, like 
HIV-1 PR, is a homodimeric aspartic protease, but each monomer comprises 125 
residues, rather than 99 residues for HIV-1 PR (Fig. 1). Studies on the HTLV-1 PR 
have been recently reviewed [6-7]. HTLV-1 PR shares 28 % sequence identity with 
HIV-1 PR [8] and both the substrate specificity and inhibition profile of the two 
enzymes are substantially different [6,8,9-11]. 
 While the structures of several retroviral proteases were determined 
previously [12,13], the structure of a truncated HTLV-1 PR lacking 9 C-terminal 
residues was determined only recently [14]. Molecular models built for the protease 
suggested that the C-terminal residues 116-125 of the HTLV-1 PR would assume a 
flexible flanking region [6,8,15]. Nevertheless, the importance of the C-terminal 
residues for the activity and function of the HTLV-1 PR is controversial. The first 
study to address the potential role of the extended C-terminal region was performed 
by Hayakawa and coworkers [15]. They found that while the extreme five C-terminal 
residues were not required for autoprocessing from a larger precursor, the residues 
115-120 were required for such activity [15]. Daenke and coworkers tested the 
inhibition effect of a decapeptide representing the last 12 residues of the HTLV-1 
protease (shown underlined in Figure 1) and found that it inhibited the activity of the 
enzyme implying the involvement of the C-terminal extra residues in the enzyme 
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dimerization [16]. However, since the nature of inhibition was not determined, the 
authors did not exclude the possibility that the peptide inhibits HTLV-1 PR by 
binding to the active site of the protease [16]. In contrast with these findings and 
suggestions, another study found the HTLV-1 enzyme form truncated C-terminally 
by 10 residues to have the same activity as the full length form in an in vitro assay 
system, although the observed catalytic constants were extremely low for both 
enzyme forms [17]. In another experiment, the 116-residue-long HTLV PR appeared 
to have 60 % activity compared to the full-length PR using a fluorometric substrate, 
although no kinetic parameters were published [14].  
To clarify the role of the C-terminal region in the activity and function of 
HTLV-1 PR, we have constructed C-terminally truncated forms of the wild type 
stabilized enzyme (HTLV-1 125 PR), shortened by 5- (HTLV-1 120 PR), 9- (HTLV-
1 116 PR) and 10-residues (HTLV-1 115 PR). Furthermore, to test whether an N-
terminal sequence extension with a His-tag could complement for the role of the C-
terminal residues, as well as to facilitate pull-down dimerization experiments, N-
terminally His-tagged proteases (His-HTLV-1 125  PR, His-HTLV-1 116 PR, His-
HTLV-1 115 PR) were also constructed, expressed, purified to homogeneity, and 
studied for activity and dimerization. Using the pull-down, gelfiltration and kinetic 
studies, our work is the first to experimentally prove the importance of the C-terminal 
residues of HTLV-1 protease in the dimer stability of the enzyme.   
  
 
 
MATERIALS AND METHODS 
 
Construction of the shortened HTLV-1 protease forms. 
 
The clone coding for the stabilized HTLV-1 PR [11] was used as template for the 
mutagenesis. This enzyme contained Ala residues in place of cysteines, and a 
mutation (Leu40Ile) protecting the enzyme from autodegradation. Previous studies 
demonstrated that the activity of the stabilized enzyme is indistinguishable from that 
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of the wild-type enzyme [11]. HTLV-1 120, 116 and 115 PR forms were generated by 
stop codon insertions using the QuikChange mutagenesis protocol (Stratagene) with 
the appropriate oligonucleotide pairs obtained from Genosys Sigma. Mutations were 
verified by DNA sequencing performed with ABI-Prism dye terminator cycle 
sequencing kit (Perkin-Elmer) and an Applied Biosystems Model 373A sequencer. 
 
 
Construction of the His-tagged 10-residue shortened HTLV-1 protease. 
 
The DNA sequence of the wild-type, and 10-residue shortened HTLV-1 protease was 
amplified from the clone coding for HTLV-1 125 PR and HTLV-1 115 PR, 
respectively, by PCR using the following primer set: forward, 5’-CCT CCA GTT 
ATA CCG TTA GAT CCC GCC-3’; reverse, 5’-CGC GGA TCC TCA CAA GAT 
TAC AGG -3’. The PCR fragments were inserted into linearized pCR-Blunt 
(Invitrogen) vector. The plasmids were digested with StuI and BamHI restriction 
enzymes (New England Biolabs) to get the final protease fragments. The N-
terminally His-tagged constructs were created by replacing the capsid coding 
sequence (originally cloned between StuI and BamHI restriction sites) of a 
recombinant HIV-1 capsid protein clone which had been created using pB6, a 
derivative of pET 11a that expresses N-His-tagged proteins (a gift from Dr. Carol 
Carter, Department of Molecular Genetics and Microbiology, S.U.N.Y. Stony Brook, 
USA). The pB6-derived plasmids were grown in DH5α Escherichia coli cells and 
purified with QIAprep spin plasmid kit (Qiagen). For the construction of 9-residue 
shortened His-tagged HTLV-1 PR a stop codon was inserted into the His-HTLV-1 
125 PR sequence using the QuikChange mutagenesis protocol (Stratagene) with 
oligonucleotide pairs used previously for generating HTLV-116 PR. Constructions 
were verified by DNA sequencing performed with ABI-Prism dye terminator cycle 
sequencing kit (Perkin-Elmer) and an Applied Biosystems Model 373A sequencer. 
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 6
Enzyme purification and assays with oligopeptide substrates.  
 
Stabilized wild-type HTLV-1 PR was purified from inclusion bodies as described 
previously [11,18]. The C-terminally truncated forms were purified using the same 
procedure. The His-tagged HTLV-1 PR forms were purified by using two 
chromatography steps. The inclusion bodies were dissolved in 50 mM Tris-HCl, pH 
8.0, 7.5 M guanidine-HCl, 5 mM EDTA, then loaded onto HisTrap column 
(Amersham-Pharmacia), which was equilibrated with 20 mM Na-phosphate, pH 7.4, 
containing 500 mM NaCl, 3M guanidine-HCl, 20 mM imidazole, 2% glycerol, 0.2% 
Triton X-100, and the PRs were eluted by using an increasing imidazole gradient (20-
500 mM) in denaturing conditions. The eluted enzymes were purified further by 
reversed-phase HPLC as described previously [11]. The correct molecular weight of 
the purified HTLV-1 PRs was verified by using a 4000 Q TRAP mass spectrometer 
(Applied Biosystems). Folding of the enzymes was performed by dialysis of the 
HPLC fractions in large excess of 25 mM formic acid, pH 2.8, and subsequently in 50 
mM sodium acetate buffer, pH 5.0, containing 100 mM NaCl. For the activity 
measurements and for purity check, folded proteases were concentrated using 
Amicon ultrafiltration devices (Amicon Ultra-15, 10 kDa cut-off). Protein 
concentration was determined by the Bradford spectrophotometric method (Bio-Rad). 
Purity of the samples was determined by SDS-polyacrylamide gel electrophoresis on 
16% gels. 10-15 µg proteins were loaded per lane. Proteins were visualized by using 
Coomassie Brillant Blue staining after the electrophoretic separation. The protease 
assays were initiated by mixing of 5 µl (8 - 8500 nM) purified enzyme with 10 µl 2x 
incubation buffer A (0.5 M potassium phosphate buffer, pH 5.6, containing 10% 
glycerol, 2 mM EDTA, 10 mM dithiothreitol, 4 M NaCl) or buffer B (100 mM 
sodium acetate, pH 5.0, 0.2 M NaCl) and 5 µl 0.01 – 3.0 mM substrate. The synthesis 
and characterization of the oligopeptide substrates were described earlier [8,11,18]. 
The substrate concentration range for kinetic measurements was selected depending 
on the approximate Km values. The reaction mixture was incubated at 37 °C for one 
hour and the reaction was stopped by the addition of 180 µl 1 % trifluoroacetic acid 
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(TFA), and an aliquot was injected onto a Nova-Pak C18 reversed-phase 
chromatography column (3.9 x 150 mm, Waters Associates, Inc.) using an automatic 
injector. Substrates and the cleavage products were separated using an increasing 
water-acetonitrile gradient (0-100%) in the presence of 0.05% TFA using a LaChrom 
HPLC system (Merck Hitachi).  Cleavage products of PR-catalyzed hydrolysis for the 
peptides were identified by amino acid analysis.  Kinetic parameters were determined 
by fitting the data obtained at less than 20% substrate hydrolysis to the Michaelis-
Menten equation by using the SigmaPlot 8.02 program (Systat Software Inc). When 
Km was sufficiently high compared to the substrate concentrations used (e.g. in 
measurements performed at low ionic strength), the specificity constant (kcat/Km) was 
obtained by dividing the first-order rate constant (determined by linear regression) by 
the active enzyme concentration present in the reaction mixture. The standard 
deviation for the kcat/Km values was calculated according to Fenner [19].  The 
standard errors of the kinetic parameters were below 20 %. Active site titration of the 
wild-type and the 5-residue shortened PRs was performed using peptide KTKVL-r-
VVQPK (IB268) where r represents a reduced peptide bond, as described for the 
wild-type enzyme [18]. 
 
 
Gelfiltration of the purified proteases. 
 
Gelfiltration experiments were performed with HTLV-1 125 PR, 120 PR and 115 PR 
using a Superdex G-75 column (Amersham Pharmacia) equilibrated with 50 mM 
sodium-acetate, pH 5.0, containing 100 mM NaCl, with the flow rate of 0.5 ml/min. 
The experiments were performed using an AKTA Purifier instrument (Amersham-
Pharmacia). Elution of the proteins was followed at 280 nm wavelength. For the 
HTLV-1 125 PR and 120 PR two consecutive runs were performed, in the first run 
1.7-1.8 mg protein was loaded, and the monomer/dimer fractions were collected. 
Most of the injected proteins eluted at the exclusion volume, due to aggregation. The 
collected monomer/dimer fraction (10-15 µg) was reinjected and analyzed for the 
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monomer/dimer ratio. For HTLV-1 115 PR purified refolded protease was directly 
injected to the column. The column was calibrated using a mixture of Bio-Rad 
gelfiltration standards (containing thyroglobulin (670 kDa), γ-globulin (158 kDa), 
ovalbumin (44 kDa), myoglobin (17 kDa), vitamin B12 (1.35 kDa) and cytidine (243 
Da) using the same buffer and flow rate. 
 
 
Pull down assay of the HTLV-1 protease forms. 
 
Pull down assays were performed with a batch technique: 50 µl portions of nickel-
charged ProBond resin (Invitrogen) were pipetted to Eppendorf tubes, then the resins 
were centrifuged down (3000 rpm) and the supernatant was removed. The gels were 
equilibrated for the assay with distilled water followed by 50 mM sodium-acetate, pH 
5.0, containing 100 mM NaCl, 1% Triton-X100 and 5% glycerol. Excess of buffer 
was removed by centrifugation at 3000 rpm for 3 min. The HPLC purified HTLV-1 
125, 120 and 115 proteases were refolded alone, or in the presence of equimolar 
amount of HPLC purified His-HTLV-1 125 PR. In another set, HPLC purified His-
HTLV-1 116 PR was refolded alone or in the presence of equimolar amount of 
HTLV-1 115 protease. Based on Bradford assay and accurate volume measurement, 
same amounts of components in the pure or mixed samples were loaded onto the 
prepared nickel-chelate resins after the refolding process. Samples were let to stand 
on the resins for 5 min at room temperature then most of the unbound proteins were 
removed by centrifugation. The remaining unbound proteins were removed from the 
resins by repetitive washing with the equilibration buffer and centrifugation steps. 
The anchored proteins were eluted from the resins by adding 50 µl of 2x SDS loading 
buffer and heating for 5 min at 95 °C, then the tubes were cooled down and 
centrifuged. The supernatants were separated on 16% SDS-PAGE and stained with 
Comassie Brillant Blue. The intensity of the bands was determined using 
densitometric measurements performed with an AlphaImager 2200 gel documentation 
system (Alpha Innotech). 
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Determination of apparent Kd values of the HTLV proteases. 
 
Specific activity values were measured in duplicates as a function of dimeric enzyme 
concentration in 50 mM sodium-acetate buffer, pH 5.0, containing 100 mM NaCl 
using 1 mM KTKVF↓VVQPK oligopeptide substrate. Samples were incubated for 1 
h at 37 ºC, and processed for HPLC analysis as described for the protease above, as 
previously used to determine the Kd  as described originally for HIV-1 protease [20]. 
Assuming that the active protease dimer (D) is in rapid equilibrium with its inactive 
monomer (M), the following equations can be used to describe the activity of the 
enzyme on oligopeptide substrate (S) [20]:  
 
       Kd                              Km        kcat  
2M  =  D     and     D + S  =  D:S → D + products 
    
  
The apparent Kd values can be obtained by plotting the relative specific activities 
against the concentration of the HTLV-1 protease forms and fitting a curve using 
“Hyperbola single rectangular 2 parameters equation” setting of SigmaPlot 8.02 
software. 
 
 
Molecular Modeling.  
 
Crystal structures of HIV-1 PR (PDB code: 1K1T [21]) and HTLV-1 116 PR (PDB 
code: 2B7F [14]) complexed with inhibitors, and a molecular model of HTLV-1 125 
PR were used for structural analysis. The nine residue long C-terminal tail of HTLV-
1 125 PR was built manually into the crystal structure of the HTLV-1 116 PR using 
Sybyl software package (Tripos). Unfavorable interactions were removed by energy 
minimization (Kollmann all atom force field [22] 10 Simplex and 100 Powell 
iterations, 8 Angstrom cut-off). Lipophilic potentials on molecular surfaces were 
generated by MOLCAD modul of Sybyl. The model of HTLV-1 125 PR is available 
from the authors upon request. 
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RESULTS 
 
The sequence alignment of HTLV-1 and HIV-1 PRs, based on crystal structures, is 
shown in Fig. 1 for the wild-type proteases and for the His-HTLV 125 PR. All the 
other constructs used in this paper contained shortened versions of this sequence or 
no His-tag (starting with the first Pro residue). The 125 residue-length protease 
(HTLV-1 125 PR) was previously characterized in detail [8,11,18]. Based on the 
active site titrations, this form folded completely, and efficiently processed the 
oligopeptide substrates at high ionic strength (Table 1). At lower ionic strength the 
enzyme exhibited an approximately thirty to eightyfold reduction in the specificity 
constants (Table 1). The beneficial effect of ionic strength, similar to that for HIV-1 
PR [23], on the catalytic activity of HTLV-1 PR has been reported earlier [24]. To 
determine the kinetic capability of the C-terminally shortened enzyme forms without 
or with an N-terminal His-tag, these proteins were expressed and purified to 
homogeneity, as demonstrated by SDS-polyacrylamide gel electrophoresis (Fig. 2). 
These purified concentrated enzymes (at least 1.7 mg/ml final concentration) were 
used for further assays. The 5-residue truncated form (HTLV-1 120 PR) also folded 
very efficiently (98 % based on active site titration performed on the freshly prepared 
and refolded enzyme), nevertheless, it showed substantially lower Km and kcat values, 
resulting in a thirty to fourtyfold decrease in the specificity constants at high ionic 
strength but only four- to sevenfold decrease at low ionic strength (Table 1). Small 
but detectable activity was observed for the HTLV-1 116 PR form at high ionic 
strength. While the wild-type and the HTLV-1 120 PR were able to efficiently cleave 
various substrates under various conditions at 25-2500-fold dilutions, no activity was 
observed for the HTLV-1 115 PR, even when it was used in the concentrated form 
(data not shown). The N-terminal histidine tag dramatically affected the kinetic 
parameters of the HTLV-1 PR forms. Only the His-HTLV-1 125 PR showed activity 
on various substrates at high ionic strength, while it was inactive at low salt 
concentration. Its Km values were higher and kcat values were much lower as 
compared to those obtained with HTLV-1 125 PR, resulting in extremely low 
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specificity constants (Table 1). These results suggest that the C-terminal residues are 
important for efficient substrate hydrolysis, and the N-terminal extra sequence with 
the His tag is not favorable for the enzyme activity. Interestingly, N-terminal 
extension of HIV-1 PR also had an unfavorable effect on the activity of the enzyme 
[25]. 
 To determine the apparent dimer stability of the HTLV-1 125 and HTLV-1 
120 PR forms, an activity-based assay originally used for HIV-1 PR [20]. The assay 
was performed in low ionic strength condition (Buffer B). As fully formed dimer 
should have a constant specific activity, the decrease of specific activity by 
decreasing enzyme concentration is considered to be due to the less efficient 
dimerization, hence, the enzyme concentration corresponding to the 50% loss in 
enzyme activity represents the apparent dissociation constant Kd [20]. Substantial 
differences were observed in the apparent dimer stability of the HTLV-1 125 PR (Kd. 
= 491 nM) and HTLV-1 120 PR (Kd. > 3000nM), as shown in Fig. 3. These results 
indicated that the removal of the C-terminal 5 residues substantially decreased the 
apparent dimer stability of the enzyme. A substantial decrease of the specific activity 
was observed for the HTLV-1 125 PR above 2500 nM concentration (data not 
shown), and a similar effect was found for the HTLV-1 120 PR above 7000 nM (data 
not shown). This effect was predicted to be due to the high aggregation tendency of 
HTLV-1 protease, as observed in the gelfiltration experiments (see below) and is in a 
good agreement with our observations of aggregation tendencies during 
crystallization of HTLV-1 PR forms. 
 To further characterize the effect of truncation on the dimer stability as well as 
dimerization capability of the enzymes, gelfiltration experiments were performed 
using the same buffer conditions as utilized for the dimerization assay. As shown in 
Fig. 4, while the wild type HTLV-1 125 PR appeared to be mostly in the dimeric 
form under the assay conditions of gelfiltration, the equilibrium was shifted towards 
the monomeric form for the HTLV-1 120 PR, while the HTLV-1 115 PR was 
completely in the monomeric form, suggesting that the elimination of the 10 residue-
long C-terminal flanking sequence detrimental for the dimerization capability of the 
enzyme in low ionic strength conditions. 
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 As the HTLV-1 115 PR and the His-tagged HTLV-1 PRs were not active at 
low ionic strength (Table 1), a pull-down assay was performed to obtain more 
information about the effect of the C-terminal residues of the HTLV-1 PR on 
dimerization. While the HTLV-1 125 PR formed heterodimer with the His tagged 
HTLV-1 125 PR with close to 1:1 molar ratio, the HTLV-1 120 and 115 PRs 
associated significantly weaker with the His-HTLV-1 125 PR (Fig. 5). Interestingly, 
the dimerization capability of the HTLV-1 115 PR was similar with the His-HTLV-1 
116 and His-HTLV-125 PRs. 
 To obtain a feasible explanation for our results, we analyzed the nature of the 
C-terminal extension in HTLV-1 PR (Fig. 1) as well as created a molecular model for 
HTLV-1 125 PR. Various surface representations of HIV-1 and HTLV-1 116 PRs 
showed substantial differences between hydrophobicities of the C-terminal regions of 
the two enzymes (Fig. 6 A and B). The more hydrophilic HIV-1 PR also showed a 
more compact structure in this region (Fig. 6A), while residues of the terminal beta-
sheet and the Arg77-Pro84 loop of the HTLV-1 116 PR formed a groove (Fig 6B). 
Based on the experimental results, we predicted that this hydrophobic groove may be 
filled by the extra C-terminal residues which may preferentially interact with the 
hydrophobic "outer" surface of the terminal beta-sheet. To obtain a molecular model 
for the full-length protease, we have incorporated the 9 missing residues into the 
crystal structure of the HTLV-1 116 PR in such a way that this interaction may occur. 
The structural requirements of this step and the characteristics of PEAKGPPVIL 
fragment (residues 116-125) were in good agreement: the PEAKGPP part was 
dominated by Pro, Gly and charged residues with strong turn-forming propensity, 
while residues of the terminal Val-Ile-Leu part had hydrophobic and beta-sheet-
forming characters. The C-terminal residues were predicted to form two new 
"strands" for the terminal beta-sheet (Fig 6C), however they were stabilized not by H-
bonds of the peptide backbone, rather by hydrophobic interactions of the side-chains. 
Interestingly, cellular aspartic proteases also have six strands in their corresponding 
beta-sheet region, but the topologies are completely different (data not shown). The 
presence of the additional C-terminal residues in the full-length protease model 
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resulted in a substantial decrease in size of the hydrophobic patch, although it did not 
disappear completely (Fig. 6D). 
 
 
DISCUSSION 
 
Based on structure-based sequence comparison, HTLV-1 PR appears to contain a 10 
residue-long C-terminal flanking sequence, as shown in Fig. 1. The C-terminal 
extension is a characteristic feature of the proteases belonging to the deltaretrovirus 
family. While some other proteases also appear to contain C-terminally extended 
sequences, none of the proteases for which the 3-dimensional structure is available 
contain such C-terminal extension [12] including the newly determined structure of 
HTLV-1 116 PR [14]. The importance of this C-terminal flanking sequence is 
controversial. In case of bovine leukemia virus (BLV), another deltaretrovirus, the C-
terminal flanking region of the PR appeared to be dispensable for the activity of 
purified recombinant protease [25], while at lease five out of the ten C-terminal 
flanking amino acid residues were required for self-processing activity of HTLV-1 
PR [15]. Inhibition by a peptide representing the C-terminal 12 amino acid residue-
long region of the protease also suggested the importance of this region in the enzyme 
dimerization [16]. However, recently a purified, N-terminally His-tagged but C-
terminally 10 residues shortened HTLV-1 PR was described, which showed an 
activity equivalent to that of the full-length His-tagged protease [17]. Surprisingly, 
both the wild-type and the shortened enzyme showed very low catalytic efficiency 
(0.004-0.006 s-1 kcat values) compared to the catalytically active HTLV-1 125 PR and 
HTLV-1 120 PR forms, described in this paper. The HTLV-1 116 PR used for 
crystallization appeared to have 60 % activity of that of the full length protease, but 
no kinetic data were provided [14], therefore the folding/activity level of this form is 
uncertain. In our hands the HTLV-1 116 PR appeared to have residual catalytic 
activity (Table 1). We have speculated that the activity of the His-HTLV-1 115 PR 
described by Herger et al. [17] might be due to the presence of N-terminal His-tag, 
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therefore, we have also expressed the HTLV-1 115 PR with an N-terminal histidine 
tag, but this form appeared to be completely inactive in our assay systems. 
Furthermore, the N-terminally His-tagged HTLV-1 116 PR did not show any activity 
(data not shown) while the activity of the His-HTLV-1 125 PR was substantially 
lower than that of the HTLV-1 125 PR (Table 1). 
 To further characterize the role of the C-terminal extension in HTLV-1 PR, 
we have determined the apparent Kd values of the HTLV-1 125 and 120 PRs using a 
specific activity-based method. The shorter enzyme appeared to have dramatically 
lower dimer stability (Fig. 3). The importance of the C-terminal residues in 
dimerization  also supported by the result of gelfiltration experiments, which showed 
that the HTLV-1 115 PR appeared only in monomeric form in low ionic strength 
conditions (Fig. 4). An aggregation effect was observed for the HTLV-1 125 PR 
when the protein concentration was increased (Fig. 3), an effect also seen for HTLV-
1 120 PR at threefold higher protein concentration (data not shown). This 
phenomenon partly explains the sustained failure of the crystallization of the full 
length HTLV-1 PR and the fact that HTLV-1 116 PR was favorably crystallized, 
although only in the presence of a ligand that is expected to strongly facilitate 
dimerization [14]. These results suggest that the C-terminal 10 residues may also 
have a critical role mediating the in vitro aggregation of the protease. 
 The results of the pull-down assay further confirmed our findings that the C-
terminal extension of the HTLV-1 PR has a critical role in dimerization in the 
absence of ligand that may also be a prerequisite for sufficient catalytic efficiency. 
There is no structural evidence for how these extended residues can contribute to the 
dimerization. Retroviral PR dimers are held together by an intricate H-bond network 
at the catalytic aspartates called the “fireman’s grip” as well as by the beta sheets 
formed by C- and N-terminal residues [12]. The two regions are not independent: in 
case of HIV protease, the residues above the beta sheet form a hydrophobic cluster 
which interacts with the side chain of the Thr residues after the catalytic aspartates. 
The side chains below the beta sheet are hydrophilic and they interact with the bulk 
solvent. Unlike in HIV-1 PR, the residues of the beta sheet exposed to the water are 
hydrophobic in HTLV-1 PR, which might explain the high aggregation tendency of 
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the enzyme. Furthermore, it also provides a surface for interaction with the residues 
of the extreme C-terminus, which may contribute to the dimer stability of the full 
length HTLV-1 protease. However, the exact way in which these residues contribute 
to the dimer stability of HTLV-1 PR requires further structural studies. We have 
created a molecular model for the positioning of the C-terminal residues. This model 
explains the importance of these residues in the dimerization process and does not 
contradict the observed high aggregation and the low crystal-forming propensities of 
the full length HTLV-1 PR. The flexibility of the C-terminal tail may allow  the 
dimer to switch between a more compact and a more open structure, in which the tail 
does not interact with the body of the PR, which may  interfere in the crystallization 
processes. It is important to note that the C-terminal tail of the HTLV-1 protease was 
also found to be critical for the infectivity of recombinant HTLV-1 virions: while the 
5-residue truncation already decreased infectivity, elimination of the 10 residues 
practically abolished infectivity in a wild-type PR sequence background (M. Mitchell 
and D. Derse, personal communication). Therefore the proposed extended 
dimerization interface of HTLV-1 PR may provide an additional target site for design 
of inhibitors against this enzyme. 
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Table 1.  Kinetic parameters determined for various HTLV-1 protease formsa
_________________________________________________________________________________________________
Buffer A ________________ Buffer B_
Enzyme form Substrate Km kcat kcat/Km kcat/Km(mM)   (s-1)   (mM-1s-1)    (mM-1s-1)
_________________________________________________________________________________________________
HTLV-1 125 PR KTKVL↓VVQPK 0.063 ± 0.004 b 10.0 ± 0.2 b 158.7 ± 10.6 b 5.41 ± 0.17c
KTKVF↓VVQPK 0.049 ± 0.006 b 16.4 ± 0.9 b 334.7 ± 44.9 b 4.16 ± 0.06c
His-HTLV-1 125 PR KTKVL↓VVQPK 0.088 ± 0.013 0.0020 ± 0.0001 0.022 ± 0.003 No cleavaged
KTKVF↓VVQPK 0.116 ± 0.014 0.021 ± 0.001  0.180 ± 0.023 No cleavaged
HTLV-1 120 PR KTKVL↓VVQPK 0.034 ± 0.003  0.150 ± 0.004    4.4 ± 0.4   0.81 ± 0.03c
KTKVF↓VVQPK 0.014 ± 0.001  0.160 ± 0.001   11.7 ± 0.4   1.03 ± 0.08c
HTLV-1 116 PR KTKVL↓VVQPK No cleavaged No cleavaged
KTKVF↓VVQPK Residual activitye No cleavaged
______________________________________________________________________________________________________________________
aMeasurements were performed at least in triplicate sets providing values within the experimental errors. A representative set is given the
table. No activity was observed for His-HTLV-1 116 PR, HTLV-1 115 PR and His-HTLV-1 115 PR forms  in buffer A or in buffer B.
bThese data are taken from Ref. (8). 
cThese values were determined using first-order kinetic conditions ([S] << Km)
dNo hydrolysis was observed neither at low nor at high protease concentration. 
eResidual activity was observed when the substrate was incubated with 3.1 µM protease in assay conditions.
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FIGURE LEGENDS 
 
Figure 1. Sequence alignment of the HIV-1 (HXB2) and HTLV-1 (CS) proteases.  
The identical residues are indicated by boxes. The sequence of the peptide reported to 
be inhibitory on the enzyme activity is underlined. The sequence of the longest 
histidine-tagged recombinant HTLV-1 protease form is also provided, where the 
stabilizing mutations (L40I, C90A, C109A) are in italics. 
 
Figure 2.  SDS-polyacrylamide gel electrophoresis of the expressed HTLV-1 
protease forms.   
Samples are indicated below the gel using the following abbreviations: H125: His-
HTLV-1 125 PR; H116: His-HTLV-1 116 PR; H115: HTLV-1 115 PR; 125: HTLV-1 
125 PR;  120: HTLV-1 120 PR; 116: HTLV-1 116 PR; 115: HTLV-1 115 PR; M, 
unstained molecular mass marker from Fermentas. The gel was stained with 
Coomassie Brillant Blue to visualize the proteins.  
 
Figure 3. Determination of the apparent dissociation constant for HTLV-1 
protease forms.  Relative specific activities were measured for the HTLV-1 125 PR 
(upper panel) and for the HTLV-1 120 PR (lower panel) as a function of dimeric 
enzyme concentration at a final substrate (KTKVFVVQPK) concentration of 1 mM, 
in 50 mM sodium acetate buffer (pH 5.0), 100 mM NaCl using an HPLC assay. The 
obtained apparent Kd values were  491 ± 119 nM for HTLV-1 125 PR and > 3000 nM 
for HTLV-1 120 PR. 
 
Figure 4. Gelfiltration of the HTLV-1 protease forms.  
Gelfiltration of the indicated HTLV-1 protease forms was performed on a Superdex 
G75 column in 50 mM sodium-acetate buffer, pH 5.0, containing 100 mM NaCl 
(Buffer B in Table 1), at 0.5 ml/min flow rate. The position of the eluted monomeric 
(M) and dimeric (D) forms is indicated. Elution volume for the standard proteins used 
for the calibration of the column under identical conditions is indicated above the 
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chromatograms. Based on the calibration, the apparent molecular weights of the 
eluted proteins are: HTLV-1 125 PR dimer: 28 kDa, monomer: 12 kDa; HTLV-1 120 
PR dimer: 24 kDa, monomer: 11 kDa; HTLV-1 115 PR monomer: 10 kDa. 
 
Figure 5. Pull-down assay of the HTLV-1 protease forms.  
SDS-PAGE of the pull-down assay samples is shown. M, unstained molecular mass 
marker from Fermentas; Protease samples are indicated below the gel using the same 
abbreviations as in Figure 2. Densitometric evaluation of gels from four independent 
experiments provided the following ratios: 125/H125: 84.9 ± 10%; 120/H125: 37.2 ± 
13.4%; 115/H125: 37.3 ± 12%; 115/H116: 43.1 ± 18.7%. 
 
Figure 6. Structural representations of the HIV-1 and HTLV-1 proteases.  
(A) Lipophilic potential of HIV-1 PR X-ray structure on Connolly-type molecular 
surface. (B) Lipophilic potential of HTLV-1 116 PR X-ray structure on Connolly-
type molecular surface. (C) Ribbon representation of HTLV-1 125 PR. Residues 1-
116 (X-ray structure) are shown in cyan (monomer A) and yellow (monomer B), 
while residues 117-125 (model) are shown in blue (monomer A) and orange 
(monomer B). The structure is shown in a view perpendicular to that of Figures A, B 
and D. (D) Lipophilic potential of HTLV-1 125 PR model on Connolly-type 
molecular surface. 
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Kádas et al., Fig. 1. 
 
 
1                    10                            20         
↓ ↓ ↓
HIV-1 PR (wt)        P Q I T L W     Q R P L V T I K I G           G Q L K 
HTLV-1 PR (wt)            P V I P L D P A R R P L I K A Q V D T Q T S H P K T I 
His-HTLV-1 125 PR MAHHHHHHGRPP V I P L D P A R R P L I K A Q V D T Q T S H P K T I
↑ ↑ ↑
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30                      40   50  
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Kádas et al., Fig. 2. 
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Kádas et al., Fig. 3  
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Kádas et al., Fig. 4 
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Kádas et al., Fig. 5 
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Kádas et al., Fig. 6 
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